180 related articles for article (PubMed ID: 23595605)
1. Improved performance of SPECT-CT In-111 capromab pendetide by correlation with diffusion-weighted magnetic resonance imaging for identifying metastatic pelvic lymphadenopathy in prostate cancer.
Hardie AD; Rieter WJ; Bradshaw ML; Gordon LL; Young MA; Keane TE
World J Urol; 2013 Dec; 31(6):1327-32. PubMed ID: 23595605
[TBL] [Abstract][Full Text] [Related]
2. Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT.
Schuster DM; Savir-Baruch B; Nieh PT; Master VA; Halkar RK; Rossi PJ; Lewis MM; Nye JA; Yu W; Bowman FD; Goodman MM
Radiology; 2011 Jun; 259(3):852-61. PubMed ID: 21493787
[TBL] [Abstract][Full Text] [Related]
3. Ten-year outcomes: the clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (Prostascint) in a cohort diagnosed with localized prostate cancer.
Ellis RJ; Kaminsky DA; Zhou EH; Fu P; Chen WD; Brelin A; Faulhaber PF; Bodner D
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):29-34. PubMed ID: 20961696
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic performance of In-111 capromab pendetide SPECT/CT in localized and metastatic prostate cancer.
Rieter WJ; Keane TE; Ahlman MA; Ellis CT; Spicer KM; Gordon LL
Clin Nucl Med; 2011 Oct; 36(10):872-8. PubMed ID: 21892036
[TBL] [Abstract][Full Text] [Related]
5. Capromab Pendetide imaging of prostate cancer.
Haseman MK; Rosenthal SA; Polascik TJ
Cancer Biother Radiopharm; 2000 Apr; 15(2):131-40. PubMed ID: 10803318
[TBL] [Abstract][Full Text] [Related]
6. Progress in SPECT/CT imaging of prostate cancer.
Seo Y; Franc BL; Hawkins RA; Wong KH; Hasegawa BH
Technol Cancer Res Treat; 2006 Aug; 5(4):329-36. PubMed ID: 16866563
[TBL] [Abstract][Full Text] [Related]
7. Utilization of (111)In-Capromab pendetide SPECT-CT for detecting seminal vesicle invasion with recurrent prostate cancer after primary in situ therapy.
Kimura M; Tsivian M; Mouraviev V; Mayes JM; Price MM; Bannister MC; Madden JF; Wong TZ; Polascik TJ
Int J Urol; 2009 Dec; 16(12):971-5. PubMed ID: 19843189
[TBL] [Abstract][Full Text] [Related]
8. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer.
Rosenthal SA; Haseman MK; Polascik TJ
Tech Urol; 2001 Mar; 7(1):27-37. PubMed ID: 11272670
[TBL] [Abstract][Full Text] [Related]
9. 111-In-capromab pendetide imaging using hybrid-γ camera-computer tomography technology is not reliable in detecting seminal vesicle invasion in patients with prostate cancer.
Tsivian M; Wright T; Price M; Mouraviev V; Madden JF; Kimura M; Wong T; Polascik TJ
Urol Oncol; 2012; 30(2):150-4. PubMed ID: 20189846
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
Raj GV; Partin AW; Polascik TJ
Cancer; 2002 Feb; 94(4):987-96. PubMed ID: 11920467
[TBL] [Abstract][Full Text] [Related]
11. Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer.
Schettino CJ; Kramer EL; Noz ME; Taneja S; Padmanabhan P; Lepor H
AJR Am J Roentgenol; 2004 Aug; 183(2):519-24. PubMed ID: 15269050
[TBL] [Abstract][Full Text] [Related]
12. Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial.
Schuster DM; Nieh PT; Jani AB; Amzat R; Bowman FD; Halkar RK; Master VA; Nye JA; Odewole OA; Osunkoya AO; Savir-Baruch B; Alaei-Taleghani P; Goodman MM
J Urol; 2014 May; 191(5):1446-53. PubMed ID: 24144687
[TBL] [Abstract][Full Text] [Related]
13. Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer.
Manyak MJ; Hinkle GH; Olsen JO; Chiaccherini RP; Partin AW; Piantadosi S; Burgers JK; Texter JH; Neal CE; Libertino JA; Wright GL; Maguire RT
Urology; 1999 Dec; 54(6):1058-63. PubMed ID: 10604708
[TBL] [Abstract][Full Text] [Related]
14. In vivo tumor grading of prostate cancer using quantitative 111In-capromab pendetide SPECT/CT.
Seo Y; Aparici CM; Cooperberg MR; Konety BR; Hawkins RA
J Nucl Med; 2010 Jan; 51(1):31-6. PubMed ID: 20008977
[TBL] [Abstract][Full Text] [Related]
15. Restricted water diffusibility as measured by diffusion-weighted MR imaging and choline uptake in (11)C-choline PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer.
Beer AJ; Eiber M; Souvatzoglou M; Holzapfel K; Ganter C; Weirich G; Maurer T; Kübler H; Wester HJ; Gaa J; Krause BJ
Mol Imaging Biol; 2011 Apr; 13(2):352-61. PubMed ID: 20490932
[TBL] [Abstract][Full Text] [Related]
16. Correction of photon attenuation and collimator response for a body-contouring SPECT/CT imaging system.
Seo Y; Wong KH; Sun M; Franc BL; Hawkins RA; Hasegawa BH
J Nucl Med; 2005 May; 46(5):868-77. PubMed ID: 15872362
[TBL] [Abstract][Full Text] [Related]
17. Preoperative lymph node staging in patients with primary prostate cancer: comparison and correlation of quantitative imaging parameters in diffusion-weighted imaging and 11C-choline PET/CT.
Vag T; Heck MM; Beer AJ; Souvatzoglou M; Weirich G; Holzapfel K; Rummeny EJ; Schwaiger M; Krause BJ; Eiber M
Eur Radiol; 2014 Aug; 24(8):1821-6. PubMed ID: 24889997
[TBL] [Abstract][Full Text] [Related]
18. Update on fused capromab pendetide imaging of prostate cancer.
Sodee DB; Nelson AD; Faulhaber PF; Maclennan GT; Resnick MI; Bakale G
Clin Prostate Cancer; 2005 Mar; 3(4):230-8. PubMed ID: 15882479
[TBL] [Abstract][Full Text] [Related]
19. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide.
Hinkle GH; Burgers JK; Neal CE; Texter JH; Kahn D; Williams RD; Maguire R; Rogers B; Olsen JO; Badalament RA
Cancer; 1998 Aug; 83(4):739-47. PubMed ID: 9708939
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases.
Budiharto T; Joniau S; Lerut E; Van den Bergh L; Mottaghy F; Deroose CM; Oyen R; Ameye F; Bogaerts K; Haustermans K; Van Poppel H
Eur Urol; 2011 Jul; 60(1):125-30. PubMed ID: 21292388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
